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Available online 17 May 2016MAP kinase phosphatase (MKP)-1 plays a pivotal role in controlling MAP kinase (MAPK)-dependent (patho)
physiological processes. Although MKP-1 gene expression is tightly regulated at multiple levels, the underlying
mechanistic details remain largely unknown. In this study, we demonstrate that MKP-1 expression is regulated
at the post-transcriptional level by 22(R)-hydroxycholesterol [22(R)-HC] through a novel mechanism.
22(R)-HC induces Hu antigen R (HuR) phosphorylation, cytoplasmic translocation and binding to MKP-
1 mRNA, resulting in stabilization of MKP-1 mRNA. The resulting increase in MKP-1 leads to suppression
of JNK-mediated inﬂammatory responses in brain astrocytes. We further demonstrate that 22(R)-HC–in-
duced phosphorylation of nuclear HuR is mediated by PKCα, which is activated in the cytosol by increases
in intracellular Ca2+ levels mediated by the phospholipase C/inositol 1,4,5-triphosphate receptor (PLC/IP3R)
pathway and translocates from cytoplasm to nucleus. In addition, pharmacological interventions reveal thatme-
tabotropic glutamate receptor5 (mGluR5) is responsible for the increases in intracellular Ca2+ that underlie
these actions of 22(R)-HC. Collectively, our ﬁndings identify a novel anti-inﬂammatory mechanism of 22(R)-
HC, which acts through PKCα-mediated cytoplasmic shuttling of HuR to post-transcriptionally regulate MKP-1
expression. These ﬁndings provide an experimental basis for the development of a RNA-targeted therapeutic
agent to control MAPK-dependent inﬂammatory responses.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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PKCα1. Introduction
Numerous experimental inﬂammatorymodels have revealedmutu-
al regulatory interactions between inﬂammation and cholesterol me-
tabolism [1]. Oxysterols are generated during cholesterol metabolism,
either by enzymatic reactions or nonenzymatic cholesterol oxidations,
or both [2]. Biological effects of oxysterols are mainly mediated by
liver X receptors (LXRs), which regulate cholesterol homeostasis by
modulating the expression of genes including ATP-binding cassette
(ABC) transporters, sterol response element-binding protein-1, and
apolipoprotein E [3]. Oxysterol-LXR signaling has been documented in
autoimmune diseases, infectious diseases, cancer, and neurodegenera-
tive diseases [4]. LXR-independent actions of oxysterols have alsosphatase-1; IP, immunoprecipi-
hosphate receptor; 22(R)-HC,
C, protein kinase C; GPCR, G
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. This is an open access article underbeen reported, with recent ﬁndings suggesting that oxysterols interact
with G protein-coupled receptors (GPCRs). For example, 22(R)-HC
and 7α,25-dihydroxycholesterol activate C-X-Cmotif chemokine recep-
tor 2 (CXCR2) [5] and Epstein-Barr virus-induced 2 (EBI2) [6], respec-
tively, and play a key role in chemotactic migration of immune cells.
Oxysterols containing 27-hydroxycholesterol, imported from the
peripheral bloodstream, cross the blood-brain barrier (BBB) [7]. Some
oxysterols can be synthesized in neurons and glial cells [8]. One
oxysterol, 22(R)-HC, has been identiﬁed in the newborn brain [9] and
shown to be present at reduced levels in postmortem brains of
Alzheimer's disease patients compared with age-related controls [10].
However, the signiﬁcance of this ﬁnding has not been clariﬁed.
Oxysterols, including 22(R)-HC, are reported to be involved in neuroin-
ﬂammation and neurodegenerative diseases [8,11], but the exact
molecular mechanism remains incompletely understood.
The mitogen-activated protein kinase (MAPK) family, which
includes extracellular signal-regulated kinase (ERK), p38 MAPK and c-
Jun. N-terminal kinase (JNK), are activated in different pathological con-
texts associated with acute or chronic inﬂammation [12]. Dual phos-
phorylation on conserved threonine (Thr) and tyrosine (Tyr) residues
of MAPKs is a prerequisite for activation of downstream events [13].
These actions are countered by MAPK phosphatases (MKPs), which
regulate MAPKs by directly dephosphorylating both residues [13].the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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leading to the suppression of MAPK-dependent inﬂammation through
de-phosphorylation of MAPKs. In previous studies, we noted that 15d-
PGJ2 and ETYA, ligands of peroxisome proliferator-activated receptor
(PPAR)-γ and PPARα, respectively, exert anti-inﬂammatory actions
that induce MKP-1, a member of the MKP family [14,15].
Various stimuli, including serum, insulin, glucagon, dexamethasone,
and stressful conditions (e.g., heat shock, hypoxia, and osmotic shock),
are known to up-regulate MKP-1 expression in various cell types [16].
Some of these stimuli share a similar signal transduction pathway for
the induction of MKP-1 expression. For example, intracellular Ca2+
and PKC activation critically contribute to the adrenocorticotropin-
and angiotensin II-induced up-regulations of MKP-1 [17,18]. Ca2+ sig-
naling also plays an important role in the transcriptional elongation of
the MKP-1 mRNA [19], and is known to up-regulate MKP-1 [17,18,20].
PKC signaling is required for the induction of MKP-1 by various stimuli,
including PMA (phorbol 12-myristate 13-acetate) [21], adrenocortico-
tropin [17], and angiotensin II [18]. However, the precise molecular
mechanism through which Ca2+/PKC signaling regulates MKP-1 ex-
pression remains to be clariﬁed.
Since MKP-1 transcript and protein have short half-lives of approxi-
mately 15 and 150min, respectively,MKP-1 ismaintained at a relatively
low level in resting cells [22]. Rapid accumulation of MKP-1 protein is
achieved through regulation of expression at both post-transcriptional
and post-translational levels. Whereas lipid mediators and stressors
induce MKP-1 expression via HuR-dependent post-transcriptional
regulation [15,22,23], dexamethasone promotes MKP-1 protein ac-
cumulation by preventing its proteasome-dependent degradation
[24]. Post-transcriptional regulation of MKP-1 mRNA is closely relat-
ed to RNA-binding proteins (RBPs), including HuR, nuclear factor-90
(NF-90), tristetraprolin (TTP) and T-cell intracellular antigen-1 (TIA-
1) [22,23,25]. HuR plays important roles in the post-transcriptional
regulation of mRNA maturation, degradation, and translation [26].
In particular, it stabilizes many short-lived mRNAs by binding to
their AU-rich 3′-untranslated regions (3′-UTRs) [27]. HuR is mainly
located in the nucleus and its cytoplasmic translocation together
with its mRNA cargo is an important step in stabilizing target
mRNAs [26,28]. The shuttling of HuR between nucleus and cytoplasm
is regulated by its speciﬁc translational modiﬁcations—phosphorylation,
methylation, and ubiquitination [29,30]. Physiologically, different stimuli
modulate the shuttling of HuR via speciﬁc intracellular signaling
cascades, such as p38 MAPK, MAPK-activated protein kinase-2 (MK2),
AMP-activated kinase (AMPK), cell-cycle checkpoint kinase 2 (CHK2),
and the protein kinase C (PKC) family members, PKCα and PKCδ [29].
In this study, we demonstrate that 22(R)-HC increases MKP-1
protein expression through stabilization of MKP-1 mRNA via a HuR-
dependent post-transcriptional regulatory mechanism, leading to sup-
pression of JNK-mediated pro-inﬂammatory responses. We further
demonstrate that HuR is phosphorylated by PKCα, which is activated
by 22(R)-HC–induced mGluR5-mediated Ca2+ signaling. This study
highlights an unexpected role of 22(R)-HC, demonstrating that 22(R)-
HC increases MKP-1 expression mainly via an mGluR5-mediated,
Ca2+/PKCα pathway. These results raise the possibility that a synergis-
tic mechanism that regulates gene expression atmultiple levels, includ-
ing the RNA level, could be exploited for the development of anti-
inﬂammatory agents, thus reducing the dose required and potentiating
therapeutic efﬁcacy.
2. Materials and methods
2.1. Reagents and antibodies
22(R)-HC, actinomycin D, 1,2-bis-(2-amino-5-aminophenoxy)
ethane-N,N,N′,N′-tetraacetic acid, tetrakis (acetoxymethyl) ester
(BAPTA-AM), lipopolysaccharide (LPS), 2-aminoethyl diphenylborinate
(2-APB), nifedipine, U73122, 2-methyl-6-(phenylethynyl)pyridine(MPEP), and SIB-1757 were purchased from Sigma-Aldrich (ST. Louis,
MO, USA). Gö6976 was purchased from Calbiochem (Darmstadt,
Germany). Antibodies against phospho-JNK (P-JNK), JNK, phospho-
p38 MAPK (P-p38), p38 MAPK, phospho-ERK (P-ERK), ERK, and PKCα
were purchased from Cell Signaling Technology (Danvers, MA, USA).
Antibodies against MKP-1, actin, HuR, glyceraldehyde-3-phosphate de-
hydrogenase (GAPDH), lamin B, TTP, TIA-1, and NF-90 were purchased
from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Antibodies
against phospho-T638, phospho-T497, and phospho-S657 PKCα were
purchased from Abcam. Antibodies against anti-glial ﬁbrillary acidic
protein (GFAP), FLAG was purchased from Sigma-Aldrich. The anti-
phospho-serine antibody was purchased from Chemicon (Darmstadt,
Germany). GSK2033 was purchased from Tocris Bioscience (Ellisville,
MO, USA).
2.2. Cell culture and RNA interference
Primary cultures of cortical astroglial cells were prepared as de-
scribed previously [22]. Small interfering RNAs (siRNA) for MKP-1,
LXR, TTP, and NF-90 were purchased from Dharmacon (Lafayette, CO,
USA), and TIA-1 siRNAwas from QIAGEN (Chatsworth, CA, USA). For si-
lencing of speciﬁc proteins, cells were transfected with siRNA (50 nM)
mixed with Lipofectamine RNAiMAX reagent (Invitrogen, Paisley, UK)
according to themanufacturer's instruction, andwere further incubated
for 48 h. The siRNA sequences used are described in Supplementary
Table S1.
2.3. Plasmids
Full-length cDNA for rat wild-type (WT) PKCαwas ampliﬁed from a
rat astrocyte cDNA library using Phusion High Fidelity DNA polymerase
(Finnzymes, Keilaranta, Finland) and the primer pair 5′-TCG CGG ATC
CGA ATT CGC TGA CGT TTA CCC G-3′ (forward) and 5′-GAC GGA GCT
CGA ATT CTA CTG CAC TTT GCA A-3′ (reverse). The cDNA was cloned
into the p3XFLAG-CMV-7.1 vector (Sigma-Aldrich) by digestion with
EcoRI. The PKCαNLSmutant [31]was created by site-directedmutagen-
esis using a QuikChange Lightning Site-directed mutagenesis kit
(Agilent Technologies, Wilmington, USA), using the newly cloned
p3XFLAG-WT PKCα as a template.
The previously generated construct encoding FLAG-tagged rat HuR
[22]wasmodiﬁed by Enzynomics (Daejeon, Korea); site-directedmuta-
genesis was used to generate the nonphosphorylatablemutants, S158A,
S221A, and S158A/S221A, and the phosphomimic mutants, S158D,
S221A, and S158D/S221D. The following primer pairs were used:
S158A, 5′-GCT GAA GCA GAA GAG GCA ATT ACC AGT TTC-3′ (forward)
and 5′-CCG TTT GTC AAA CCG GAT AAA GGC-3′ (reverse); S221A, 5′-
GCC CCT ATG GGT GTA GAT CAC ATG AGT G-3′ (forward) and 5′-GAA
CCT GAA TCT CTG TGC CTG GTG ATG-3′ (reverse); S158D, 5′-GAT GAA
GCA GAA GAG GCA ATT ACC AGT TTC-3′ (forward) and 5′-CCG TTT
GTC AAA CCG GAT AAA GGC-3′ (reverse); and S221D, 5′-GAC CCT ATG
GGT GTA GAT CAC ATG AGT GG-3′ (forward) and 5′-GAA CCT GAA
TCT CTG TGC CTG GTG ATG-3′ (reverse).
2.4. Reverse transcription and quantitative real-time PCR analysis
Reverse transcription and quantitative real-time polymerase chain
reaction (RT-qPCR) analyses were performed as described previously
[22]. Brieﬂy, total RNA was isolated using RNAiso Plus (TaKaRa, Otsu,
Japan), and cDNA was synthesized using avian myeloblastosis virus re-
verse transcriptase (New England Biolabs) and oligo(dT) primers
(Promega, Madison, WI, USA), according to the manufacturer's instruc-
tions. For qPCR, ampliﬁcation reactions were performed using a Ther-
mal Cycler Dice Real Time System (TaKaRa) with SYBR Premix Ex Taq
master mix (TaKaRa) according to the manufacturer's instructions.
The primers used for qPCR (Bioneer, Daejeon, Korea) are described in
Supplementary Table S2.
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For measuring cytokine levels, astrocytes were seeded onto 35-mm
dish at 5 × 105 cells/dish. Interleukin (IL)-1β andmonocyte chemotactic
protein (MCP)-1 levels in culture medium were determined using
commercial enzyme-linked immunosorbent assay (ELISA) kits
(Koma Biotech, Seoul, Korea), consisting of antibodies and rat pro-
tein standards, based on the manufacturer's instructions. Optical
density was determined on an iMark microplate absorbance reader
(Bio-Rad, Philadelphia, PA, USA) at a wavelength of 450 nm.
2.6. Subcellular fractionation
Harvested cells were resuspended in Buffer A, consisting of 50 mM
Tris-HCl (pH 7.4), 100 mM NaCl, 1 mM dithiothreitol (DTT), 2.5 mM
MgCl2, 0.1% Nonidet P-40 (NP-40), protease inhibitor cocktail
(Calbiochem), phosphatase inhibitor cocktail (GenDepot, Barker, TX,
USA), 1 mM ethylenediaminetetraacetic acid (EDTA]), 5 mM sodium
ﬂuoride (NaF) and 1 mM sodium vanadate. Cell suspensions were
allowed to stand on ice for 5 min, and then sheared by passing through
a 26-gauge needle 20 times. Nuclei were separated from the cytoplasm
by centrifugation at 1000 ×g for 10 min at 4 °C. Nuclei were washed
twice with Buffer A, lysed in Buffer B (50 mM Tris-HCl pH 7.4,
100 mM NaCl, 1 mM DTT, 2.5 mM MgCl2, 1% NP-40, 1% Triton X-100,
1 mM PMSF, protease inhibitor cocktail, phosphatase inhibitor cocktail,
5 mM NaF, 1 mM sodium vanadate, 1 mM EDTA), and disrupted by
sonication.
2.7. Western blotting
Cells were lysed in RIPA buffer (50 mM Tris-HCl pH 7.4, 150 mM
NaCl, 0.5% NP-40, 1 mM DTT, 1 mM PMSF, protease inhibitor cocktail,
phosphatase inhibitor cocktail, 5 mM NaF, 1 mM sodium vanadate,
1 mM EDTA). Protein concentration in lysates was determined using
the Bio-Rad protein assay (Bio-Rad) according to themanufacturer's in-
structions. Proteins (10–20 μg) were separated by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) on 10% poly-
acrylamide gels and transferred to a nitrocellulose membrane. Mem-
branes were probed using the indicated primary and secondary
antibodies and developed using an enhanced chemiluminescence de-
tection kit (WESTSAVE Gold; AbFrontier, Seoul, Korea). Band intensities
were quantiﬁed using ImageJ software (National Institutes of Health,
Bethesda, MD, USA).
2.8. Immunoprecipitation (IP)
Cells were lysed in modiﬁed RIPA buffer (50mMTris-HCl pH 7.4, 1%
NP-40, 100 mM NaCl, 2.5 mMMgCl2, 1 mM DTT, 1 mM PMSF, protease
inhibitor cocktail, phosphatase inhibitor cocktail, 5mMNaF, 1mMsodi-
um vanadate, 1 mM EDTA). Lysates were mixed with 1 μg of anti-
phosphoserine antibody and incubated at 4 °C on a rocker overnight.
Immune complexes were collected with protein G-agarose beads
(Upstate Biotechnology, Lake Placid, NY), and the level of HuR protein
in lysates was assessed by Western blot analysis.
2.9. UV cross-link ribonucleoprotein (RNP)-IP
UV cross-link RNP-IP assays were performed as described by Chang
et al. [32]. Brieﬂy, cells were exposed to UVC (400 mJ/cm2), and cyto-
plasmic extracts were immunoprecipitated using an anti-HuR antibody
or control mouse monoclonal IgG. Immune complexes were collected
using protein G-agarose and washed ﬁve times. After proteins were
digested by incubation at 50 °C for 1 h with proteinase K solution
(30 mM Tris-HCl, 10 mM EDTA, 1% SDS, 100 μg/ml proteinase K,
100 U/ml RNaseOUT), mRNA was puriﬁed using RNAiso Plus and ana-
lyzed by conventional PCR or real-time qPCR.2.10. Immunostaining
Astrocytes cultured on coverslips were ﬁxed with 4% paraformalde-
hyde in phosphate-buffered saline (PBS) at 25 °C for 10min and perme-
abilized by incubating in PBS containing 0.1% Triton X-100 for 5 min.
Fixed cells were incubated with anti-HuR, anti-lamin B, anti-GFAP,
and anti-PKCα antibodies at 4 °C overnight. Immunoreactive proteins
were visualized by incubation with Alexa Flour 488- or Alexa Flour
543-conjugated secondary antibodies (Molecular Probes, Eugene, OR,
USA). Cells were mounted with DAPI-containing mounting solution
and observed under a confocal microscope (LSM510, Carl Zeiss, Jena,
Germany). Intensity proﬁles of PKCα and lamin B immunostaining
were measured using Zeiss LSM510 software.
2.11. Immune complex kinase assay
Immune complex kinase assays were performed as described by
Yoon et al. [33]. Brieﬂy, PKCα was collected by incubating cell lysates
(200 μg) with an anti-PKCα antibody at 4 °C overnight, followed by in-
cubationwith proteinG-agarose. Afterwashing immune complexesﬁve
times with PKC buffer (50 mM Tris-HCl pH 7.4, 10 mM MgCl2, 1 mM
NaF, 1 mM Na3VO4, protease inhibitor cocktail, phosphatase inhibitor
cocktail, 5 mM sodium ﬂuoride, 1 mM sodium vanadate, 1 mM EDTA),
kinase activity was initiated by resuspending the immunoprecipitates
in 20 μl of PKC buffer containing 10 μCi of [γ-32P]ATP (PerkinElmer)
and 5 μg/ml of puriﬁed recombinant HuR. The reactions were allowed
to proceed for 30 min at 30 °C and were terminated by addition of
SDS sample buffer. The reaction mixtures were boiled for 5 min, sepa-
rated by SDS-PAGE, and transferred onto nitrocellulose membranes.
HuR and 32P-labeled HuR were quantiﬁed by densitometric analysis of
Western blots and autoradiographs, respectively.
2.12. Measurement of cytosolic Ca2+
Cellswere loadedwith Fura-2/AMor Fluo-4/AM (Invitrogen, Paisley,
UK) for 50 min at 37 °C and then washed. Fluorescence was monitored
at 2-s intervals on the stage of an inverted microscope (Nikon, Tokyo,
Japan). Cells treated with Fura-2/AM were analyzed by exciting at 340
and 380 nm and examining ﬂuorescence emitted at 510 nm using a
spectroﬂuorometer (Photon Technology International, Brunswick, NJ,
USA). Cells treated with Fluo-4/AM were analyzed by exciting at
488 nm and examining ﬂuorescence emitted at 543 nm using an A1R
confocal microscope (Nikon) while superfusing cells with an HCO3−
buffered solution containing the indicated agents at a constant rate of
2 ml/min. The 340/380 nm ﬂuorescence ratio or ﬂuorescence at
488 nm was used to calculate [Ca2+]i concentration.
2.13. Statistical analysis
Statistical signiﬁcance was determined using the Student's t-test or
ANOVA,with p-values b 0.05 considered signiﬁcant. Results are present-
ed as themeans and standard deviation (S.D.) or standard error (S.E.) of
at least three independent experiments.
3. Results
3.1. 22(R)-HC induces MKP-1 expression in an LXR-independent manner
Some oxysterols have been reported to exert anti-inﬂammatory ef-
fects; however, the underlying mechanisms are largely unknown. In
previous studies, we found that JNK-mediated inﬂammatory responses
are mitigated by some anti-inﬂammatory materials through induction
of MKP-1 [14,15,22]. Based on this ﬁnding, we screened several
oxysterols and related LXR ligands for their ability to induce MKP-1 ex-
pression. These compounds showed differential abilities to induceMKP-
1 (Supplementary Fig. S1A to C). Among them, 22(R)-HCwas chosen for
Fig. 1. 22(R)-HC increases MKP-1 expression in an LXR-independentmanner. (A to D) Primary astrocytes were treatedwith the indicated concentrations of 22(R)-HC for 6 h (A and B) or
with 20 μM22(R)-HC for the indicated times (C andD). (E and F)Astrocyteswere transfectedwith control siRNA or siRNA against LXRα and/or LXRβ. After 48 h, the cellswere treatedwith
20 μM22(R)-HC for 6 h.MKP-1mRNA and protein levelsweremeasured by RT-qPCR (E) andWestern blot analysis (F), respectively. ABCA1, LXRα and LXRβmRNA levelsweremeasured
by RT-qPCR (E). The ratio of MKP-1 band intensity to Actin band intensity in controls was deﬁned as 1. (G) Astrocytes were treated with 20 μM22(R)-HC for 3 h with or without the LXR
antagonist, GSK2033. The mRNA levels of MKP-1 (a) and ABCA1 (c) weremeasured by RT-qPCR. The protein levels of MKP-1 and actin (b) were measured byWestern blot analysis. Data
are presented as means ± S.D. of three independent experiments (*p b 0.05 and **p b 0.01).
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a physiological concentration range [34] and is an endogenous
oxysterol. First, we examined time- and concentration-dependent
MKP-1 induction by 22(R)-HC. Treatment with 22(R)-HC (5–30 μM)
for 6 h caused a concentration-dependent induction of MKP-1 mRNA
and protein expression without causing cellular toxicity (Fig. 1A and
B, Supplementary Fig. S1D and E). The time dependence of MKP-1
mRNAand protein induction showed somewhat different patterns. Spe-
ciﬁcally, MKP-1 protein expressionwas consistently increased from 1 to
12 h by treatment with 20 μM 22(R)-HC (Fig. 1D), whereas increases in
mRNA levels were apparent starting at 1 h, peaked at 3 h, and then
slightly decreased thereafter (Fig. 1C).The differential ability of 22(R)-HC among oxysterols to induce
MKP-1 expression (Supplementary Fig. S1A and B) suggests a possible
LXR-independent action. Thus, we tested receptor dependency by
knocking down LXR using siRNA. MKP-1 induction by 22(R)-HC was
not signiﬁcantly different between control siRNA-transfected cells and
cells transfected with LXRα or LXRβ siRNA, which effectively reduced
the expression of their target genes (Fig. 1E and F). To further conﬁrm
that these effects were independent of LXR, cells were stimulated with
22(R)-HC in the absence or presence of GSK2033, a potent LXR inhibitor
(Fig. 1G). Although co-treatment with GSK2033 clearly blocked the
22(R)-HC-induced expression of ABCA1 (Fig. 1G; c), this treatment
had little effect on the mRNA and protein expression levels of MKP-1
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expression in an LXR-independent manner.
3.2. HuR mediates MKP-1 induction by 22(R)-HC
Next, we examined the molecular mechanism underlying 22(R)-
HC–induced MKP-1 up-regulation. The robust and rapid induction of
MKP-1 mRNA by 22(R)-HC (Fig. 1C) suggests a transcriptional or post-
transcriptional mechanism. To exclude the possibility of a post-
translational mechanism, we examined the effect of 22(R)-HC on the
stability of MKP-1 protein. The degradation rate of MKP-1 protein was
determined after eliminating de novo protein synthesis using cyclohex-
imide. As shown in Supplementary Fig. S2A, 22(R)-HC did not affect the
degradation rate of MKP-1 protein, a result very similar to that obtained
with 15d-PGJ2 (a negative control) [22], whereas the proteasome inhib-
itor MG132 stabilized MKP-1 protein as expected.
Since transcription initiation of the MKP-1 gene is constitutively
activated under basal conditions [19] and acute induction of MKP-1 in
response to diverse stimuli is accompanied by the stabilization of
MKP-1mRNA [22,23],we examined the effect of 22(R)-HCon the stabil-
ity of MKP-1 mRNA. To this end, we measured the decay rate of MKP-1
mRNA after stopping de novo RNA synthesis using actinomycin D. The
half-life of MKP-1 mRNA in untreated astrocytes was 10.7 min, which
gradually increased to 20.5, 27.1 and 53.8 min in cells treated with
22(R)-HC for 3, 6 and 12 h, respectively (Fig. 2A). In contrast, the half-
life of GAPDH, a housekeeping gene, was not affected during the tested
time period. mRNA stability mainly depends on RBPs, especially HuR,
NF-90, TTP, and TIA-1 in the case of MKP-1 [15,22,23,25]. Accordingly,Fig. 2. HuR is responsible for 22(R)-HC–induced MKP-1 expression. (A) The half-life (t1/2) of M
22(R)-HC for the indicated times. Transcription was halted by treatment with 2 μg/ml actinomy
normalized to GAPDHmRNA level. The value at time 0 was taken as 100%, and the amount (%)
transfected with control siRNA or siRNAs against HuR (B and C), NF-90, TTP, or TIA-1 (D). Aft
determined by RT-qPCR (B) and Western blot analysis (C and D), respectively. Graphs (right)
of actin bands in 22(R)-HC-treated cells. Ratio of band intensity in control siRNA-transfected
S.D. of three independent experiments (*p b 0.05 and **p b 0.01).we tested the involvement of candidate RBPs using siRNAs targeting
each RBP. siRNA-mediated knockdown of HuR inhibited 22(R)-HC–
induced MKP-1 mRNA expression in the cytoplasm and whole cells
(Fig. 2B), and was associated with MKP-1 protein accumulation
(Fig. 2C). Knockdown of other RBPs, including TTP, NF-90 and TIA-1,
failed to inhibit 22(R)-HC–induced expression of MKP-1 protein
(Fig. 2D). These results indicate that HuR is mainly involved in 22(R)-
HC–induced MKP-1 expression.
Next, we examined whether 22(R)-HC affected HuR expression, but
we did not observe any signiﬁcant difference in HuR protein expression
between treated and untreated cells (Fig. 3A). HuR resides in the nucle-
us under basal conditions, and its export to the cytoplasm is required to
stabilize HuR target mRNAs [26,28]. Therefore, we examined whether
22(R)-HC induced cytoplasmic accumulation of HuR. 22(R)-HC
(20 μM) caused a steep increase in the level of HuR protein in the cyto-
plasm beginning at 1 h, producing a maximal effect at 6 h (Fig. 3B, a).
Cytoplasmic accumulation of HuR was evident in cells exposed to con-
centrations of 22(R)-HC N15 μM (Fig. 3B, b). In contrast, no signiﬁcant
differencewas observed in the protein abundance of HuR in the nucleus
(Fig. 3B). Thismay suggest that only a small amount of HuRmoves from
the nucleus to the cytoplasm under 22(R)-HC stimulation. These results
were conﬁrmed by immunochemistry using an anti-HuR antibody.
Whereas HuR immunoﬂuorescence was detected exclusively within
the nucleus in control cells, diffuse immunoﬂuorescence throughout
the cytoplasm in addition to the nucleus was detected in 22(R)-HC–
treated cells (Fig. 3C). Unlike 22(R)-HC, 7-ketocholesterol (7-KC)
did not induce cytoplasmic accumulation of HuR (Supplementary
Fig. S3).KP-1 and GAPDHmRNA decay was determined by treating primary astrocytes with 20 μM
cin D (act. D) for the indicated times. MKP-1mRNA level was assessed using RT-qPCR and
of mRNA remaining was plotted on a logarithmic scale. (B to D) Primary astrocytes were
er 48 h, cells were treated with 22(R)-HC for 6 h. MKP-1 mRNA and protein levels were
show ratios of intensities of individual MKP-1, HuR, NF-90, TTP, and TIA-1 bands to that
, 22(R)-HC-treated cells was arbitrarily deﬁned as 1. The data are presented as means ±
Fig. 3. 22(R)-HC induces cytoplasmic translocation of HuR and increases HuR binding to MKP-1 mRNA. (A and B) Primary astrocytes were treated with 22(R)-HC (10 or 20 μM) for the
indicated times (A), with 20 μM 22(R)-HC for the indicated times (B, a), or with different concentrations of 22(R)-HC for 6 h (B, b). (A) HuR and actin proteins in whole-cell lysates
were examined by Western blot analysis. (B) Cytoplasmic (left) and nuclear (right) fractions were prepared as described in the Materials and methods section, and the protein levels
of HuR, GAPDH (a cytoplasmic marker), and lamin B (a nuclear marker) were determined by Western blot analysis. Graphs (middle) show the relative band intensities of the HuR
protein. (C) Primary astrocytes treated with 20 μM 22(R)-HC for 6 h were immunostained using antibodies speciﬁc to HuR (red) and GFAP (green), an astrocyte marker. Nuclei were
stained with DAPI (blue). The enlarged images show digitally magniﬁed views of the boxed area. The dotted lines in the enlarged images indicate nucleus boundary. Scale bar =
20 μm. Right, Intensity proﬁles show intensity curves for HuR along the arrows in the images on the left. (D) Upper, Primary astrocytes were treated with 20 μM 22(R)-HC for 6 h. The
bindings of the MKP-1, COX-2 and GAPDH mRNAs to HuR were examined by UV-crosslink RNP-IP using control IgG and anti-HuR antibodies, as described in the Materials and
methods section. Graph, the levels of the MKP-1 and COX-2 mRNAs in immunoprecipitates are shown as the fold differences of the abundances observed in HuR-IP complexes versus
control IgG-IP complexes. Bottom, Western blots were probed for GAPDH and lamin B to conﬁrm the fractionation. The GAPDH immunoblot was used as a control for loading to the
RNP-IP (input). (E) Primary astrocytes were treated with different concentrations of 22(R)-HC for 6 h (upper) or with 20 μM 22(R)-HC for the indicated times (bottom). RNP-IP was
performed as described above. The data are presented as means ± S.D. of three independent experiments (*p b 0.05 and **p b 0.01).
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interacted with MKP-1 mRNA, we performed RNP-IP experiments on
control and 22(R)-HC–treated cells. HuR-bound MKP-1 mRNA was
greatly increased in 22(R)-HC–treated cells (Fig. 3D). Similar results
were obtained for cyclooxygenase-2 (COX-2) mRNA, which was usedas a positive control because its expression is known to be regulated
post-transcriptionally by HuR [35]. As a negative control, we assessed
the level of GAPDH mRNA in HuR IP complexes, and found that it was
comparable to that in control IgG IP complexes and was unchanged by
22(R)-HC treatment. Further analysis revealed that 22(R)-HC dose-
Fig. 4.PKCα is involved inHuRphosphorylation and cytoplasmic translocation andMKP-1 expression in 22(R)-HC–treated cells. (A to C) Primary astrocytes transfectedwith control siRNA
or PKCα siRNAwere exposed to 22(R)-HC (20 μM) for 6 h. (A) HuR, PKCα, GAPDH, and lamin B protein levels in cytoplasmic fractionswere examined byWestern blot analysis. (B)MKP-1
mRNA level in cytoplasmic extractsweredeterminedbyRT-qPCR. (C)MKP-1, PKCα, and actin protein levelswere determined byWestern blot analysis. Graph shows ratios of intensities of
individual PKCα andMKP-1 bands to that of actin bands in 22(R)-HC–treated cells transfectedwith speciﬁc siRNAs. Ratio of band intensity in control siRNA-transfected, 22(R)-HC-treated
cells was arbitrarily deﬁned as 1. (D) Astrocyteswere treatedwith 20 μM22(R)-HC for the indicated times, and phospho-PKCα (Ser-657, Thr-497, and Thr-638)was assessed byWestern
blot analysis. (E to H) Primary astrocyteswere treatedwith 22(R)-HC (20 μM) for 6 h in the absence or presence of Gö6976 (PKCα inhibitor). (E)HuR, GAPDH, and lamin B protein levels in
cytoplasmic fractions were examined by Western blot analysis. Graph (upper) shows relative intensities of HuR protein bands. (F) MKP-1 mRNA levels were examined by RT-qPCR.
(G) MKP-1 and actin protein levels in whole-cell lysates were examined by Western blot analysis. Graph shows relative intensities of MKP-1 bands normalized to those of actin bands.
(H) Phosphoserine-containing proteins were immunoprecipitated from cytoplasmic fractions using an anti-phosphoserine antibody. HuR protein was detected by Western blot
analysis. (I) Primary astrocytes were treated with 20 μM 22(R)-HC for the indicated times (left) or with different concentrations of 22(R)-HC for 6 h (right). Immune complex kinase
assays using immunoprecipitated PKCα were performed as described in Materials and methods. Unlabeled and 32P-labeled HuR protein were quantiﬁed by densitometric analysis of
Western blots and autoradiographs, respectively. (J to N) Astrocytes expressing the indicated FLAG-tagged wild-type, nonphosphorylatable mutant (S158A, S221A, and S158A/S221A),
and phosphomimic mutant (S158D, S221D, and S158D/S221D) HuR proteins were incubated for 3 h with or without 22(R)-HC. (J) The mRNA levels of MKP-1 were examined by RT-
qPCR. (K and L) Equal amounts of proteins from whole cells and cytoplasmic fractions were separated and subjected to Western blot analysis for MKP-1, FLAG-HuR, HuR, actin, lamin
B, and GAPDH. (M) The bindings of the MKP-1 and GAPDH mRNAs to HuR were examined by UV-crosslink RNP-IP using control IgG and anti-HuR antibodies, as described in the
Materials and methods section. (N) The half-lives (t1/2) of the MKP-1 and GAPDH mRNAs were determined as described in Fig. 2A. The data are presented as means ± S.D. of three
independent experiments (*p b 0.05 and **p b 0.01).
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mRNA (Fig. 3E). Collectively, these ﬁndings indicate that 22(R)-HC pro-
motes cytoplasmic accumulation of HuR and its binding to MKP-1
mRNA, leading to MKP-1 mRNA stabilization and an increase in MKP-
1 expression.
3.3. 22(R)-HC activates PKCα, leading to HuR-dependent regulation of
MKP-1 expression
These ﬁndings raise the question of how HuR is activated and
translocated from the nucleus to the cytoplasm. Several protein kinases
are reported to be involved in nucleo-cytoplasmic translocation of HuR.
Among them are PKCα and PKCδ, which are reported to be involved in
post-transcriptional regulation of HuR target genes [36–38]. Moreover,
PKC activity is involved in MKP-1 expression [39,40]. We tested the in-
volvement of PKCα using a siRNA approach. siRNA-mediated PKCα
knockdown profoundly impaired cytoplasmic accumulation of HuR in
22(R)-HC–treated cells (Fig. 4A), resulting in the inhibition of MKP-1
mRNA (Fig. 4B) and protein (Fig. 4C) expression. PMA (phorbol 12-
myristate 13-acetate), a PKC activator, also increased themRNA expres-
sion and stability of MKP-1 (Supplementary Fig. S4B and C).
Next, we examinedwhether 22(R)-HC alters the phosphorylation of
PKCα, which is phosphorylated at three positions in the kinase core:
Thr-497, Thr-638, and Ser-657 [41]. We found that 22(R)-HC induced
the transient phosphorylation of PKCα Ser-657 (Fig. 4D), which releases
mature PKCα from the cytoskeleton to the cytosol [41]. However, the
phosphorylations of PKCα Thr-497 and Thr-638, which are essential
for the kinase activity of PKCα, were not affected by 22(R)-HC treat-
ment. These results indicated that 22(R)-HC promotes the activation
of PKCα through phosphorylation of Ser-657.
Experiments using Gӧ6976, a pharmacological inhibitor of PKCα,
showed a similar inhibitory effect on the cytoplasmic translocation of
HuR (Fig. 4E) and resulting MKP-1 mRNA (Fig. 4F) and protein
(Fig. 4G) expression. Since cytoplasmic translocation of HuR is preceded
by its phosphorylation [36–38], we tested whether PKCαmediated the
phosphorylation of cytoplasmic HuR. Gӧ6976 treatment effectively
prevented the phosphorylation of HuR in the cytoplasm (Fig. 4H).
To determine if 22(R)-HC directly regulates PKCα activity, we
performed in vitro kinase assays of recombinant PKCα using
[γ-32P]ATP and puriﬁed HuR as a substrate. The addition of various
activators that bind to sites in the regulatory domain of PKCα, including
Ca2+, diacylglycerol (diolein), phospholipids (phosphatidylserine), and
PMA, increased the minimal basal phosphorylation of HuR by PKCα
(Supplementary Fig. S4A). In contrast, the addition of 22(R)-HC to this
cell-free system did not change the phosphorylation of HuR, which re-
ﬂects PKCα activity. This indicates that 22(R)-HC does not directly
bind to PKCα.
Immune complex kinase assays measuring PKCα activity further
showed that 22(R)-HC indirectly increased PKCα activity to enable
the phosphorylation of HuR. As shown in Fig. 4I, the time course and
concentration-dependence of HuR phosphorylation were very similar
to those for cytoplasmic translocation of HuR (Fig. 3B).
Since PKCα phosphorylates HuR Ser-158 and Ser-221, leading to the
nuclear export of HuR [36], we examined whether the addition of
nonphosphorylatable mutants of HuR could inhibit the 22(R)-HC–
induced up-regulation of MKP-1. The expression of double mutant
S158 A/S221 A, which was produced by substituting Ala for Ser-158
and Ser-221 of HuR, had maximal inhibitory effects on the 22(R)-HC–
induced alterations in the mRNA expression of MKP-1 (Fig. 4J; left),
the protein expression of MKP-1 (Fig. 4K; whole lysates), the nuclear
export of HuR (Fig. 4K; cytoplasm), the binding of HuR to the MKP-1
mRNA (Fig. 4M), and the stability of the MKP-1 mRNA (Fig. 4N;
upper). Single mutations of HuR (S158A or S221A) yielded somewhat
smaller inhibitions compared to the double mutation (Fig. 4J, K, M and
N). As shown in Fig. 4K (cytoplasm), the nuclear export of endogenous
HuR was slightly decreased to a degree similar to that seen in the HuRmutants. This result may reﬂect the oligomerization of HuR, which
was previously reported [42]. Next, we performed substitutions of Asp
for HuR Ser-158 or Ser-221 (to mimic the negative charge of a phos-
phate group), and examinedwhether thesemutations could functional-
ly induce MKP-1 expression in a manner analogous to the action of
22(R)-HC. Indeed, the expressions of phosphomimic mutants, HuR
S158D, S221D and S158D/S221D, effectively imitated the actions of
22(R)-HC in the absence of this agent (Fig. 4J, L to N). Although HuR
Ser-158 and Ser-221 are both required for the actions of 22(R)-HC,
our results indicate that phosphorylation of Ser-221 has a greater effect.
Collectively, these results indicate that the 22(R)-HC–induced activa-
tion of PKCα mediates the HuR-dependent regulation of MKP-1
expression.
3.4. 22(R)-HC–induced nuclear translocation of PKCα underlies cytoplas-
mic translocation of HuR and subsequent MKP-1 induction
For cytoplasmic PKCα to phosphorylate HuR, which is localized pre-
dominantly in the nucleus, a preceding PKCα nuclear translocation step
is required. To test this, we assessed the effect of 22(R)-HC on the sub-
cellular localization of PKCα.Western blot analyses showed that nuclear
PKCα was detectable beginning 30 min after 22(R)-HC treatment, and
increased up to 3 h, depending on the treatment duration (Fig. 5A). In
line with these data, immunostaining experiments showed that PKCα
immunoﬂuorescence increasedwithin the nucleus in 22(R)-HC–treated
cells (Fig. 5B). To conﬁrm the role of nuclear PKCα in 22(R)-HC–in-
duced, HuR-dependent MKP-1 expression, we performed experiments
using a nuclear translocation-defective mutant PKCα. To this end, we
generated vector constructs containing FLAG-tagged WT PKCα and a
mutant in which the nuclear localization signal (NLS) was mutated
[31] (Fig. 5C). Whereas 22(R)-HC increased translocation of WT PKCα
from the cytoplasm to the nucleus, mutant PKCα remained in the cyto-
plasm (Fig. 5D), and effectively prevented the phosphorylation of HuR,
as compared to that in cells expressing wild-type PKCα (Fig. 5E).
Notably, the interaction between HuR and MKP-1 mRNAwas markedly
attenuated in mutant PKCα-transfected cells (Fig. 5F), leading to de-
creased expression of MKP-1 mRNA (Fig. 5G) and protein (Fig. 5H).
Taken together, these data demonstrate that nuclear localization of
PKCα is responsible for 22(R)-HC–induced, HuR-dependent MKP-1
expression.
3.5. PKCα/HuR-mediatedMKP-1 induction by 22(R)-HC is dependent on an
increase in cytosolic Ca2+ concentration
Still unanswered question is how22(R)-HC initiates PKCα activation
and nuclear translocation. Next, we tested whether 22(R)-HC induced
PKCα activation through Ca2+ mobilization and a subsequent increase
in cytosolic Ca2+ concentration. 22(R)-HC induced repetitive Ca2+
spikes in astrocytes (Fig. 6A). Notably, sequestration of intracellular
Ca2+ by treatment of 22(R)-HC–treated cells with the cell-permeable
Ca2+ chelator, BAPTA-AM, inhibited nuclear translocation of PKCα
(Fig. 6B), as well as Ser-phosphorylation (Fig. 6C) and cytoplasmic
translocation (Fig. 6D) of HuR, resulting in a decrease in MKP-1 mRNA
(Fig. 6E) and protein (Fig. 6F) levels. BAPTA-AM did not affect the
protein levels of HuR (Supplementary Fig. S5B) or MKP-1 (Fig. 6F, lane
5) in whole-cell lysates. Collectively, these results suggest that 22(R)-
HC triggers an increase in cytosolic Ca2+ concentration, leading to
PKCα/HuR-mediated MKP-1 induction.
Next, we performed experiments to clarify the source of cytosolic
Ca2+, using several pharmacological inhibitors of Ca2+ regulation.
Under conditions in which extracellular Ca2+ was depleted by pre-
treatment with the cell-impermeable Ca2+ chelator EGTA, 22(R)-
HC was still capable of inducing nuclear import of PKCα (Fig. 6G;
left), cytoplasmic translocation of HuR (Fig. 6G; right), and expres-
sion of MKP-1 (Fig. 6H). Consistent with this, application of nifedi-
pine to block L-type Ca2+ channels did not affect the action of
Fig. 5. 22(R)-HC increases nuclear import of PKCα. (A) Astrocytes were treatedwith 20 μM22(R)-HC for the indicated times. PKCα protein levels in nuclear fractionswere determined by
Western blot analysis. Lamin B and GAPDH were used as markers of nuclear and cytoplasmic fractions, respectively. Graph shows relative band intensities. (B) Left, Primary astrocytes
treated with 22(R)-HC (20 μM) for 1 h were immunostained using antibodies speciﬁc to PKCα (red) and lamin B (green), a nuclear marker. Scale bar = 10 μm. Right, Intensity proﬁles
show intensity curves for PKCα and lamin B along the arrows in the images at left. (C) A schematic depicting the structural domains of the PKCα protein. NLS in WT PKCα and
substituted amino acids in the mutant are shown. (D to H) Primary astrocytes were transfected with FLAG-tagged WT or mutant PKCα. After 48 h, cells were treated with 22(R)-HC
for 3 h. (D) Ectopic PKCα (FLAG-PKCα) and HuR in cytoplasmic and nuclear factions were determined by Western blot analysis. (E) Phosphoserine-containing proteins were
immunoprecipitated from cytoplasmic fractions using an anti-phosphoserine antibody. Western blot analysis was performed using antibodies speciﬁc for HuR, FLAG, lamin B, and
GAPDH. (F) MKP-1 mRNA binding to HuR was quantiﬁed by UV-crosslink RNP-IP using control IgG and anti-HuR antibodies, as described in Materials and methods. MKP-1 mRNA
levels were measured using RT-qPCR. MKP-1 mRNA levels in immunoprecipitates are presented as fold differences in abundance of the corresponding mRNAs in the HuR-IP complex
compared with those in the IgG-IP complex. (G) MKP-1 mRNA levels in cytoplasmic fractions were measured by RT-qPCR. (H) MKP-1 protein levels in whole-cell lysates were
detected by Western blot analysis. Graph shows relative intensities of MKP-1 protein bands normalized to those of actin bands. The data are presented as means ± S.D. of three
independent experiments (*p b 0.05).
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inhibitor 2-APB (2-aminoethoxydiphenyl borate) [43] and the phos-
pholipase C (PLC) inhibitor U73122 [44] strongly blocked 22(R)-
HC–induced events. EGTA, 2-APB, nifedipine, and U73122 all failed
to affect the protein levels of HuR in whole-cell lysates (Supplemen-
tary Fig. S5C). Collectively, these ﬁndings strongly suggest that Ca2+
mobilization in 22(R)-HC–treated astrocytes is mediated by PLC/
IP3R-regulated processes.3.6. mGluR5 mediates 22(R)-HC–induced increases in cytosolic Ca2+
concentration
It was recently reported that some oxysterols directly bind to GPCRs
and modulate immune responses [5,6,45]. Since 22(R)-HC has been re-
ported to be a ligand of CXCR2 [5], which mediates IL-8–induced Ca2+
signaling through PLCβ1 activation [46,47], we investigated whether
CXCR2 was capable of functioning as a direct binding partner of
Fig. 6. 22(R)-HC increases cytosolic Ca2+ levels via the PLC/IP3R pathway. (A) Cytosolic Ca2+ levels in primary astrocytes treatedwith 22(R)-HC (20 μM)were determined as described in
Materials andmethods. (B to F) Primary astrocyteswere treatedwith 22(R)-HC (20 μM) for 3 h (B to E) or 6 h (F) in the absence or presence of increasing concentrations of BAPTA-AM, an
intracellular Ca2+ chelator. (B) PKCα, lamin B, and GAPDH protein levels in nuclear fractions were examined by Western blot analysis. (C) Phosphoserine-containing proteins were
immunoprecipitated from cytoplasmic fractions using an anti-phosphoserine antibody. HuR protein was detected by Western blot analysis. (D) HuR, GAPDH, and lamin B protein
levels in cytoplasmic fractions were examined by Western blot analysis. (E) MKP-1 mRNA levels in cytoplasmic fractions were measured by RT-qPCR. (F) MKP-1 and actin protein
levels in whole-cell lysates were examined byWestern blot analysis. Graph shows relative intensities of MKP-1 bands normalized to those of actin bands. (G and H) Primary astrocytes
were treated with vehicle, nifedipine (10 μM), 2-APB (20 μM), or U73122 (5 μM) in the presence of EGTA (2 mM). After 1 h, cells were treated with 22(R)-HC for 3 h. (G) PKCα, lamin
B, and GAPDH protein levels in nuclear fractions (left) and HuR, GAPDH, and lamin B protein levels in cytoplasmic fractions (right) were examined by Western blot analysis. (H) MKP-
1 and actin protein levels in whole-cell lysates were determined byWestern blot analysis. The data are presented as means ± S.D. of three independent experiments (**p b 0.01).
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fected by SB225002, a CXCR2 antagonist, or by siRNA-mediated knock-
down of CXCR2 (Supplementary Fig. S6A and B).
Next, we examined whether other GPCRs were able to mediate
22(R)-HC–induced MKP-1 expression. Among the many astrocytic
GPCRs, mGluRs, particularly mGluR5 and mGluR3, are predominantly
expressed [48]. In particular, mGluR5 activates PLC and leads to robust
oscillatory changes in intracellular Ca2+ [48]. Co-treatment with
MPEP, a selective mGluR5 antagonist, completely abrogated 22(R)-
HC–induced Ca2+ spikes (Fig. 7A). This result indicates that mGluR5
mediates Ca2+ mobilization in 22(R)-HC–treated astrocytes. Gӧ6976
treatment or HuR silencing did not inhibit the 22(R)-HC-induced eleva-
tion of intracellular Ca2+. Unlike control or HuR-silenced cells, the
elevated intracellular Ca2+ concentration slowly decreased in Gӧ6976-
treated cells because intracellular Ca2+ oscillations are regulated by
negative feedback from PKCα [49]. These results suggest thatFig. 7. 22(R)-HC increases MKP-1 expression and cytosolic Ca2+ in an mGluR5-dependent ma
presence of MPEP (20 μM; an mGluR5 antagonist). Right, 22(R)-HC was added to Gö6976 (
described in the Materials and methods section. (B to E) Primary astrocytes were treated wi
MPEP. (B) PKCα, lamin B, and GAPDH protein levels in nuclear fraction were determined by W
were determined by Western blot analysis. (D) MKP-1 mRNA levels were measured by RT-qPC
blot analysis. (F and G) Primary astrocytes were treated with 22(R)-HC (20 μM) for 3 h in th
were measured by RT-qPCR. (G) MKP-1 and actin protein levels in whole-cell lysates were de
(100 pM) in the absence or presence of Gö6976 (2 nM) for 3 h (H). Primary astrocytes we
(100 pM) for 3 h (I). MKP-1, HuR, and actin protein levels were determined by Western bl
(*p b 0.05 and **p b 0.01).22(R)-HC–induced mGluR5 activation-mediated Ca2+ mobilization
is upstream of PKCα and HuR.
Co-treatment with MPEP and 22(R)-HC also inhibited the subse-
quent nuclear translocation of PKCα (Fig. 7B) and cytoplasmic translo-
cation of HuR (Fig. 7C), leading to suppression of MKP-1 mRNA
(Fig. 7D) and protein (Fig. 7E) expression. To further conﬁrm the specif-
ic role of the mGluR5, we used SIB-1757, another mGluR5 antagonist.
SIB-1757 also reduced 22(R)-HC–induced MKP-1 mRNA (Fig. 7F) and
protein (Fig. 7G) expression. In contrast, EGLU (ethyl glutamate), an an-
tagonist ofmGluR3, did not affect 22(R)-HC–inducedMKP-1 expression
(Supplementary Fig. S6C). MPEP and SIB-1757 did not alter the protein
levels of HuR in whole-cell lysates (Supplementary Fig. S6D). To further
examine whether mGluR5 is involved in MKP-1 expression, we exam-
ined whether activation of mGluR5 induced MKP-1 expression. A
mGluR5 agonist, DHPG also induced MKP-1 expression, which is
inhibited by Gӧ6976 treatment (Fig. 7H) and HuR silencing (Fig. 7I).nner. (A) left, Primary astrocytes were treated with 22(R)-HC (20 μM) in the absence or
2 nM)-treated or HuR-silencing astrocytes. Cytosolic Ca2+ levels were determined as
th 22(R)-HC (20 μM) for 3 h in the absence or presence of increasing concentrations of
estern blot analysis. (C) HuR, GAPDH, and lamin B protein levels in cytoplasmic fraction
R. (E) MKP-1 and actin protein levels in whole-cell lysates were determined byWestern
e absence or presence of increasing concentrations of SIB-1757. (F) MKP-1 mRNA levels
termined by Western blot analysis. (H and I) Primary astrocytes were treated with DHPG
re transfected with control or HuR siRNAs. After 48 h, the cells were exposed to DHPG
ot analysis. The data are presented as means ± S.D. of three independent experiments
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increases in cytosolic Ca2+ concentration and subsequent MKP-1 ex-
pression, although we were unable to determine whether 22(R)-HC
binds to mGluR5.
3.7. 22(R)-HC–induced MKP-1 expression inhibits JNK-mediated induction
of pro-inﬂammatory genes
Since MKP-1 is a primary regulator of MAPK signaling pathways
including JNK, p38 MAPK, and ERK, we explored the inhibitory effects
of 22(R)-HC on MAPK-mediated inﬂammatory responses in LPS-
stimulated astrocytes. 22(R)-HC treatment induced MKP-1 expression
in LPS-stimulated cells, leading to the dephosphorylations of JNK, p38
MAPK, and ERK (Fig. 8A). LPS treatment induced the expressions of
the representative pro-inﬂammatory genes, MCP-1 and IL-1β, mainly
through the JNK and p38 MAPK pathways (Supplementary Fig. S7).
SP600125, a speciﬁc JNK inhibitor, suppressed the LPS-induced expres-
sions of MCP-1 and IL-1β (Fig. 8B). Consistentwith the inhibitory action
of SP600125, 22(R)-HC also inhibited the LPS-triggered inductions of
MCP-1 and IL-1β (Fig. 8B). The siRNA-mediated silencing of MKP-1
completely reversed the 22(R)-HC–induced suppression ofMAPK phos-
phorylations (Fig. 8C), MCP-1 expression, and IL-1β expression (Fig. 8D
and E). In addition, Gӧ6976 treatment (Fig. 8F and G) and HuR silencing
(Fig. 8H and I) had similar inhibitory effects on these anti-inﬂammatory
actions of 22(R)-HC. These results demonstrate that 22(R)-HC exerts
anti-inﬂammatory actions by acting throughMKP-1 induction to inhibit
MAPK signaling.
4. Discussion
In this study, we demonstrated a novel anti-inﬂammatory mecha-
nism in which 22(R)-HC acts through induction of MKP-1 to suppress
expression of JNK-mediated inﬂammatory genes. 22(R)-HC regulates
MKP-1 expression mainly at the post-transcriptional level through
PKCα-mediated HuR activation. Further, we showed that mGluR5 is
responsible for the mobilization of cytosolic Ca2+ through PLC/IP3R,
leading to PKCα-mediated HuR translocation from the nucleus to the
cytoplasm and MKP-1 expression (Fig. 8J).
Oxysterols, which freely traverse the BBB, have been explored as
potential targets for treatment of neurodegenerative diseases, including
Alzheimer's disease [50]. 22(R)-HC and its stable analogues protect
neuronal cells from β-amyloid–induced cytotoxicity by binding to β-
amyloid [10,51]. In this study, we demonstrated that 22(R)-HC func-
tions as an anti-inﬂammatory molecule in rat astrocytes (Fig. 8).
22(R)-HC–induced MKP-1 expression blocked MAPK phosphorylation
(Fig. 8A and C), resulting in inhibition of JNK- and p38 MAPK-
dependent expression of the pro-inﬂammatory genes, MCP-1 and IL-
1β (Fig. 8B, D, and E). In the brain, chronic expression of MCP-1 and
IL-1β causes breakdown of the BBB and excessive recruitment of neu-
trophils and microglia, leading to chronic inﬂammation and pathologi-
cal conditions [52,53]. Caprospinol, developed based on 22(R)-HC,
binds to β-amyloid monomers and prevents the formation of amyloid
plaques [51]. However, it lacks the ability to induce MKP-1 expression
(Supplementary Fig. S1C). Accordingly, combined treatment with
oxysterols acting through different mechanisms is expected to exert
synergistic therapeutic effects against degenerative brain diseases.
MKP-1 is induced by multiple intracellular signaling pathways in
response to various stimuli. Recently, we and others showed that
HuR-mediated post-transcriptional regulation plays an important role
in MKP-1 expression [22,23]. The cellular localization and/or activity
of HuR are modulated by phosphorylation of HuR serine or threonine
residues by various intracellular kinases, including the PKC family
members PKCα and PKCδ. Moreover, PKC activation is required for the
induction of MKP-1 expression by various stimuli, such as PMA [21],
adrenocorticoprotein [17] and angiotensin II [18]. However, the precise
mechanism by which PKC regulates MKP-1 expression is as yetunknown. Here, we demonstrate the underlying molecular mechanism
by which 22(R)-HC activates PKCα and promotes downstream events,
showing that HuR is phosphorylated and exported to the cytoplasm,
where phosphorylated HuR exhibits increased binding to MKP-1
mRNA and ultimately leads to an increase in MKP-1 expression (Fig. 4).
MKP-1 induction under various conditions is dependent on an in-
crease in intracellular Ca2+ [17,18,54]. In line with this, our study
showed that an increase in intracellular Ca2+ is essential for 22(R)-
HC–induced PKCα activation and subsequent downstream events
(Fig. 6). The ﬁnding that removal of extracellular Ca2+ did not block
22(R)-HC–induced MKP-1 expression (Fig. 6H) indicates that release
of Ca2+ from an intracellular source contributes to the rise in cytosolic
Ca2+ concentration. It has recently been demonstrated that a nuclear
PLC/IP3R/PKC pathway is capable of generating nuclear Ca2+ signals
that effectively promote the expression of related genes [55,56], sug-
gesting that this pathway may directly regulate the phosphorylation
of nuclear HuR. However, in our case, it is likely that nuclear Ca2+
makes a minimal contribution to 22(R)-HC actions because PKCα is
activated in the cytoplasm before it is imported into the nucleus
(Figs. 4 and 5).
Intracellular Ca2+ can simultaneously regulate multiple cellular
functions by binding to proteins containing Ca2+-binding domains.
Our ﬁndings demonstrate that Ca2+ signaling triggers PKCα/HuR-
dependent MKP-1 mRNA stabilization. In addition to this post-
transcriptional regulation, Ca2+ signaling may control transcrip-
tion of the MKP-1 gene. Ryser et al. suggested that, under basal
conditions, MKP-1 transcription has a strong tendency to stall at
an elongation step in the ﬁrst exon and that Ca2+ signaling is important
for release of this elongation block [19]. Therefore, we cannot rule out
the possibility that induction of MKP-1 expression by 22(R)-HC is syn-
ergistically regulated at the transcriptional level in addition to the
post-transcriptional level through Ca2+ signaling.
The Ca2+ source and timing of Ca2+ release into the cell are impor-
tant for activation of individual signalingpathways. Similar to 22(R)-HC,
7-KC treatment also induced an increase in cytosolic Ca2+ (Supplemen-
tary Fig. S5A). However, it neither translocated HuR to the cytoplasm
(Supplementary Fig. S3) nor inducedMKP-1 expression (Supplementa-
ry Fig. S1A). This divergent behaviormay reﬂect the different patterns of
intracellular Ca2+ mobilization generated by the two oxysterols.
Whereas 22(R)-HC induced repetitive cytosolic Ca2+ spikes (Fig. 6A),
7-KC caused a sustained increase in cytosolic Ca2+ levels (Supplemen-
tary Fig. S5A). In line with our data, treatment with 7-KC caused a sim-
ilar pattern of Ca2+ pulses in other cell types [57,58], where the increase
in cytosolic Ca2+ induced by 7-KCwas shown to trigger apoptosis. Thus,
the different Ca2+ signals induced by 22(R)-HC and 7-KC lead to differ-
ent downstream events.
Although LXR is best known as a receptor for 22(R)-HC, our data
showed that it is not involved in 22(R)-HC–induced MKP-1 expression
(Fig. 1E to G). Recent reports have shown that several oxysterols have
other binding targets in addition to LXRs [5,6,59]. Nedelcu et al. demon-
strated that Smoothened (Smo), a G protein-coupled receptor that is a
component of the hedgehog signaling pathway, contains a binding site
for 20(S)-hydroxycholesterol within a cysteine-rich domain that is
shared bymost GPCRs [59]. 22(R)-HC has also been reported to bind di-
rectly to CXCR2 [5], although this interaction is not involved in the in-
duction of MKP-1 by 22(R)-HC reported here (Supplementary Fig. S6A
and B). Instead, pharmacological interventions showed that mGluR5 is
responsible for 22(R)-HC–induced MKP-1 expression (Fig. 7), although
we have not yet determined whether mGluR5 is a direct target (or re-
ceptor) for 22(R)-HC.
Under basal conditions, our group and others have found that the
MKP-1 mRNA is unstable, with a half-life of b45 min [22,23]. However,
the MKP-1 protein has a half-life of 120 min [22]. Because the MKP-1
protein has a longer half-life than its transcript, a slight increase in the
half-life of the transcript may be sufﬁcient to trigger protein accumula-
tion. In fact, while the abundance of the MKP-1 mRNA reached a
Fig. 8. 22(R)-HC acts through increasedMKP-1 expression to inhibit JNK-mediated induction of pro-inﬂammatory genes. (A and B) Primary astrocytes were treatedwith 20 μM22(R)-HC
(A andB) for 1 h, and then exposed to LPS (100ng/ml) for 30min (A) or 3 h (B). (A)Westernblot analysiswas performedusing antibodies speciﬁc for phospho-JNK (P-JNK), JNK, phospho-
p38MAPK (P-p38), p38MAPK (p38), phospho-ERK (P-ERK), ERK,MKP-1, and actin. (B) ThemRNA levels ofMCP-1 and IL-1βweremeasured by RT-qPCR. (C to E) Primary astrocyteswere
transfectedwith control or MKP-1 siRNA. After 48 h, the cells were exposed to 22(R)-HC (20 μM) for 1 h, and then further incubatedwith LPS (100 ng/ml) for 30min (C), 3 h (D), or 24 h
(E). Protein (C) andmRNA (D) levels were assayed byWestern blot analysis and RT-qPCR, respectively. (E) The protein levels of MCP-1 and IL-1β in media were determined using ELISA.
Error bars represent S.E. (F and G) Primary astrocytes were treated with 22(R)-HC (20 μM) in the absence or presence of Gö6976 (2 nM) for 1 h, and then further incubated with LPS
(100 ng/ml) for 30 min (F) or 3 h (G). (H and I) Primary astrocytes were transfected with control or HuR siRNAs. After 48 h, the cells were exposed to 22(R)-HC (20 μM) for 1 h, and
then further incubated with LPS (100 ng/ml) for 30 min (H) or 3 h (I). Protein (F and H) and mRNA (G and I) levels were assayed by Western blot analysis and RT-qPCR, respectively.
(J) A proposed model for how 22(R)-HC confers anti-inﬂammatory functions through the mGluR5-mediated and Ca2+/PKCα/HuR-dependent induction of MKP-1. The data are
presented as means ± S.D. (B, D, G, and I) or means ± S.E. (E) of three independent experiments (*p b 0.05 and **p b 0.01).
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MKP-1 consistently increased to 12 h (Fig. 1C and D).
Although HuR silencing inhibited 22(R)-HC–induced MKP-1 mRNA
expression (Fig. 2B), it did not change the 22(R)-HC–induced stabiliza-
tion of the MKP-1 mRNA (Supplementary Fig. S2C). However, MKP-1
mRNA stability was increased in 22(R)-HC-treated cells (Fig. 2A). Also,
the results from our experiments using ectopic wild-type and mutant
HuRs (Fig. 4N) strongly suggest that 22(R)-HC stabilizes the MKP-1mRNA through an HuR-dependent mechanism. We cannot currently
suggest a precise molecular mechanism that explains why HuR silenc-
ing does not affect the 22(R)-HC–induced stabilization of the MKP-1
mRNA. However, we offer a clue that could explain this phenomenon.
Since PMA directly activates PKCα, it is likely that PMA and 22(R)-HC
share a signaling pathway responsible for mediatingMKP-1 expression.
As seen for 22(R)-HC, HuR silencing did not change the PMA-induced
stabilization of the MKP-1 mRNA (Supplementary Fig. S4C). In contrast,
1069H. Kim et al. / Biochimica et Biophysica Acta 1859 (2016) 1056–107015d-PGJ2–induced MKP-1 mRNA stabilization is known to be modulat-
ed by bothHuR silencing and ectopic HuR overexpression [22]. HuR Ser-
158 and Ser-221, which are phosphorylated by PKCα, are located in the
RNA recognition motif 2 (RRM2) and hinge region of HuR, respectively,
whereas Cys-245,which is the 15d-PGJ2–binding residue [22], is located
in RRM3. Thus, we propose that the differential effects of HuR silencing
may reﬂect some post-translationalmodiﬁcation of HuR. Future work is
warranted to elucidate the precise molecular mechanism underlying
these differences.
In summary, we have demonstrated that 22(R)-HC induces MKP-1
expression through a PKCα/HuR-dependent post-transcriptional regu-
latory mechanism, resulting in suppression of JNK-dependent inﬂam-
mation. Interestingly, we found that mGluR5 is a novel target of
22(R)-HC and is responsible for its downstream events. Our ﬁndings
identify the molecular mechanism that underlies 22(R)-HC actions as
a potential therapeutic molecule for neurodegenerative diseases.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbagrm.2016.05.008.
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